A carregar...
Adalimumab for induction of remission in Crohn's disease
BACKGROUND: Adalimumab is an IgG1 monoclonal antibody that targets and blocks tumor necrosis factor‐alpha, a pro‐inflammatory cytokine involved in the pathogenesis of Crohn's disease (CD). A significant proportion of people with CD fail conventional therapy or therapy with biologics or develop...
Na minha lista:
| Publicado no: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Ltd
2019
|
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6953260/ https://ncbi.nlm.nih.gov/pubmed/31742665 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012878.pub2 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|